eFT508 + Avelumab
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Conditions
Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Trial Timeline
Sep 18, 2017 → May 13, 2019
NCT ID
NCT03258398About eFT508 + Avelumab
eFT508 + Avelumab is a phase 2 stage product being developed by eFFECTOR Therapeutics for Microsatellite Stable Relapsed or Refractory Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03258398. Target conditions include Microsatellite Stable Relapsed or Refractory Colorectal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03258398 | Phase 2 | Completed |
Competing Products
11 competing products in Microsatellite Stable Relapsed or Refractory Colorectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Evorpacept (ALX148) + Cetuximab + Pembrolizumab | Eli Lilly | Phase 2 | 52 |
| grapiprant + grapiprant and pembrolizumab | Merck | Phase 1 | 33 |
| Bevacizumab + Capecitabine + Pembrolizumab | Merck | Phase 2 | 52 |
| MK-3475 + INCB024360 | Merck | Phase 1/2 | 41 |
| AMG 436 | Amgen | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Copanlisib + Nivolumab | Bristol Myers Squibb | Phase 1/2 | 40 |
| Ipilimumab + Nivolumab + Cobimetinib + Daratumumab + BMS-986016 | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| Balstilimab + Botensilimab | Agenus | Phase 2 | 44 |